Sitagliptin and metformin are different oral prescription medicines for type 2 diabetes: a DPP-4 inhibitor and a biguanide. They have different product labels and safety reviews, and a fixed-dose combination is a separate product rather than an automatic equivalent to taking two prescriptions.
Sitagliptin vs Metformin: Product, Formulation and Prescription Differences
Sitagliptin and metformin are both prescription medicines used in Type 2 diabetes, but they are different drugs with different classes, product forms, labeling, and generic-market histories. A product comparison is useful for understanding what appears on a prescription or pharmacy label; it should not be used to decide which medicine is “better” for an individual patient.
| Product feature | Sitagliptin | Metformin |
|---|---|---|
| Drug class | DPP-4 inhibitor | Biguanide |
| Common U.S. oral forms | Film-coated tablets | Immediate-release tablets and multiple extended-release tablet products |
| Common current strengths | 25 mg, 50 mg, 100 mg | IR commonly 500 mg, 850 mg, 1000 mg; ER strength sets vary by product and include 500 mg with 750 mg or 1000 mg products |
| Brand example | Januvia | Multiple historical/current brand and generic formulations; generic metformin dominates the U.S. product landscape |
| Generic status | FDA-approved generics now exist | Broad multi-manufacturer generic market |
| U.S. prescription status | Prescription only | Prescription only |
| Fixed-dose combination context | Available combined with metformin in products such as Janumet | Available alone and in multiple fixed-dose combination products |
What is sitagliptin?
Sitagliptin is a DPP-4 inhibitor. Januvia is the branded sitagliptin tablet. Current labeling lists 25 mg, 50 mg, and 100 mg oral tablets and identifies Januvia as a prescription drug for adults with Type 2 diabetes.
FDA approved the first generic sitagliptin phosphate tablet in December 2025. Current DailyMed records now show multiple generic sitagliptin labels, including products from Teva and Apotex. Generic approval expands the product landscape; for a specific prescription, contact the pharmacy to confirm which generic manufacturer is currently available.
What is metformin?
Metformin is a biguanide. It has a much broader generic product landscape, with numerous current immediate-release and extended-release products.
Immediate-release metformin labels commonly list 500 mg, 850 mg, and 1000 mg tablets. Extended-release products are more varied: current labels include products with 500 mg and 750 mg strengths and others with 500 mg and 1000 mg strengths. That means a prescription for “metformin ER” should be matched to the exact product and strength rather than treated as a generic description of one universal tablet.
Why might a prescriber use one, the other, or both?
The drugs act through different pharmacologic pathways and are labeled for glycemic control in Type 2 diabetes. A prescriber may select one medicine or use medicines from different classes together based on the patient’s clinical situation, treatment goals, kidney function, tolerability, other medications, contraindications, and current guidelines.
This page does not rank sitagliptin against metformin for effectiveness. The important product-level point is that they are not substitutes for each other. A 100 mg sitagliptin tablet is not a counterpart to a 1000 mg metformin tablet simply because both are oral Type 2 diabetes medicines.
Combination products: sitagliptin plus metformin
FDA-approved fixed-dose combination products contain both active ingredients. Janumet is a current example. Its label identifies sitagliptin plus metformin hydrochloride in one prescription tablet for adults with Type 2 diabetes.
Current product records include Janumet tablets containing 50 mg sitagliptin with either 500 mg or 1000 mg metformin hydrochloride, among other labeled configurations and related extended-release products.
A fixed-dose combination can simplify the number of tablets in a regimen, but it also fixes the amount and formulation of each ingredient in that product. Separate sitagliptin and metformin prescriptions are therefore not automatically identical to a particular combination tablet.
Generic and branded access differences
Metformin has an extensive generic market and is often inexpensive, but price depends on formulation, strength, package size, payer rules, and pharmacy. Sitagliptin now has FDA-approved generic products, yet a patient may still encounter differences among brand Januvia, generic manufacturers, insurer formularies, and pharmacy supply.
Useful questions at the pharmacy include:
- Is the prescription written for Januvia or for sitagliptin generally?
- If it is metformin, is it immediate release or extended release?
- What exact strength and dosage form were prescribed?
- If a manufacturer changed, are the active ingredient, strength, and formulation unchanged?
- Does the plan cover brand, generic, or a combination product differently?
- Is prior authorization or another formulary rule involved?
- Would a switch between separate tablets and a fixed-dose combination require a new prescription or prescriber approval?
Contact Valencia Town Center Pharmacy to confirm current availability and coverage for sitagliptin, Januvia, metformin, or Janumet prescriptions.
Safety differences should not be oversimplified
Metformin labeling includes a boxed warning for lactic acidosis and important renal-function precautions. Sitagliptin labeling includes warnings and precautions involving pancreatitis, heart failure risk in the DPP-4 inhibitor class, renal dosing considerations, serious hypersensitivity reactions, severe joint pain, and bullous pemphigoid.
The two products therefore have different safety and monitoring considerations. A short web comparison cannot determine which medicine is appropriate for an individual patient, and it should not be used to change a dose or replace one prescription with another.
For more product detail, see Sitagliptin and Januvia, Metformin IR and ER, or the broader Type 2 Diabetes & Metabolic Medications index.